In the setting of cancer, HMGB1 signalling through its innate immune system receptors TLR2 and TLR4 (toll-like receptors 2 and 4) is important for an antitumour immune response in breast cancer patients. The gene discussed is HMGB1; the disease is breast carcinoma.